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Abstract
Aim: To compare the results of fl uorine-18 (¹8F) fl uorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) and contrast enhanced computed tomography (ceCT) in 
the assessment of renal cell carcinoma (RCC) recurrences when ceCT had suspected lesions for local 
recurrence and/or distant metastases. 
Methods: A total of 22 patients (14 Male, 8 Female; mean age: 59±9 years) who were referred to 
perform 18F-FDG PET/CT for restaging of RCC were included in this study. All patients had suspected 
lesions in thoracal and/or abdominal ceCT for local recurrence and/or distant metastases before PET/CT. 
A retrospective analysis of the ¹8F-FDG PET/CT results was compared with ceCT results. The compatibility 
ratios were calculated and accuracy of the 18F-FDG PET/CT was determined. Aggrement between 18F-FDG 
PET/CT and ceCT was calculated using kappa statistics. 
Results: The overall concordance rate between the two imaging modalities was 32% (7/22 patients). 
The rate of concordance for local recurrence was 86% (Kappa:0.67), and for distant metastases was 68% 
(Kappa:0.40). Distant metastases were also separately investigated and the two imaging methods showed 
a concordance of 86% (Kappa:0.70) for distant lymph node, 86% (Kappa:0.67) for lung, 91% (Kappa:0.64) 
for liver and 86% (Kappa:0.33) for bone and 95% for spleen.
Conclusion: 18F-FDG PET/CT is not enough alone in the detection of local recurrence and distant 
metastases of RCC. On the other hand, evaluation of 18F-FDG PET/CT and ceCT together signifi cantly 
improves the detection of RCC recurrence. A negative 18F-FDG PET/CT may contribute to exclusion of 
suspected metastatic lesions, unless they are milimetric.
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Renal cell carcinoma (RCC) is the most common type of 
kidney cancer in adults, and it is also known to be the most 
lethal of all the genitourinary tumors [1]. RCC is generally 
silent and is generally detected incidentally by abdominal 
ultrasonography or contrast enhanced computed tomography 
(ceCT) which is performed for some other indications. 
Primary treatment for RCC is radical or partial nephrectomy. 
However, metastasis is seen in 20-30% of the patients who 
have undergone surgery. The rate of metastasis at diagnosis 
20-30% and solitary metastasis is found in 5% of the patients 
[2,3]. Metastasis is a strong predictor of bad prognosis [4], 5 
years survival rates are reported as less than 10% [5,6]. Early 
detection and management of metastatic disease is crucial to 
improve prognosis and quality of life. 
ceCT is currently used imaging modality for staging and 
restaging of RCC. Although ceCT has been used for the detection 
of the localization of recurrent or metastatic disease, it has 
some limitations in the differentiation of the recurrence from 
postoperative changes and in the detection of intraabdominal 
lymph node metastases. ceCT is also risky for it may cause renal 
functional damage and allergy to contrast agent may develop. 
Nowadays, Fluorine-18 (F) fl uorodeoxyglucose (FDG) 
positron emission tomography/computed tomography (PET/
CT) is a hybrid imaging modality which can provide anatomic 
and functional information together and it has been used for 
staging and restaging of several cancers. 18F-FDG PET (non-
hybrid) and 18F-FDG PET/CT also has been performed for 
staging and restaging of RCC. It has been shown in several 
studies; 18F-FDG PET and 18F-FDG PET/CT did not have a role 
for the primary diagnosis of RCC, because of urinary excretion 
of the radioisotope [7-12]. However, it seems to be more 
effective in the detection of distant metastases [8,10].
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The purpose of this study was to compare the results of 
fl uorine-18 (18F) fl uorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) and contrast 
enhanced computed tomography (ceCT) in the assessment of 
renal cell carcinoma (RCC) recurrences when CT had suspected 
lesions for local recurrence and/or distant metastases.
Material and Method
Patient group
A total of 22 patients (14 M, 8 F; mean age: 59.09±11.71, 
range: 34-74 years) who were referred to perform 18F-FDG 
PET/CT for restaging of RCC were included in this study. 2 
patients have undergone two PET/CT scans. Before 18F-FDG 
PET/CT, all patients had suspected lesions in thoracal and/or 
abdominal ceCT for local recurrence and/or distant metastases. 
The retrospective analysis of ceCT results was compared with 
the 18F-FDG PET/CT results. 
18F-FDG PET/CT
18F-FDG PET/CT images were acquired with a GE Discovery 
ST PET/CT scanner. During imaging, patients were under at 
least 6 hour fasting and checked whether or not their blood 
glucose levels were under 150 mg/dl. Oral or intravenous 
contrast agents were not given to the patients. Whole body 
18F-FDG PET/CT imaging was performed approximately 1 hour 
after an intravenous injection of 8-10 mCi 18F-FDG while the 
patients were in supine position from the vertex to the proximal 
femur. During the waiting period the patients rested in a quiet 
room without administrating muscle relaxant. PET images 
were acquired for 4 minutes per bed position and emission 
PET images were reconstructed with non-contrast CT images 
obtained from the patients with the use of a standardized 
protocol involving 140 kV, 70 mA, a tube rotation time of 0.5 
s per rotation, a pitch of 6 and a section thickness of 5 mm. 
The patients were allowed to breathe normally during the 
procedure. Attenuation-correction was done by PET/CT fusion 
images on three planes (transaxial, coronal and sagittal) and 
was reviewed by a Xeleris Workstation (GE Medical System). 
Image analysis 
Whole body 18F-FDG PET/CT images were interpreted 
visually and semi-quantitatively by two experienced nuclear 
medicine physicians by consensus. The comparison was made 
between foci showing increased uptake and background/blood 
pool activity. Their anatomic confi rmation was made with CT 
images. The criterion for malignancy was accepted as a FDG 
hypermetabolism at the site of the pathological changes on CT 
or a marked focal hypermetabolism at the physiological uptake 
sites. 
Statistical analysis
The results of 18F-FDG PET/CT and ceCT studies were 
compared in terms of the local recurrence and distant 
metastases. Then the aggrement between two imaging 
techniques were evaluated by Kappa statistics. SPSS version 16.0 
(SPSS Inc; Chicago, Illinois, USA) was used for the statistical 
analysis. The concordance and discordance between two 
imaging methods were investigated by checking the reability. 
In the most of the patients, histopathological confi rmation 
could not be possible. So sensitivity, spesifi city, positive and 
negative predictive value and accuracy could not be calculated.
Results 
Before 18F-FDG PET/CT, all the patients had undergone 
nephrectomy (4 partial and 18 radical). Three patients also 
had undergone lymph node dissections. Primary tumor 
localizations were the right side in 10 patients and the left 
side in the rest of the patients. Before 18F-FDG PET/CT, all the 
patients had suspected lesions in thoracal and/or abdominal 
ceCT for local recurrence and/or distant metastases. The mean 
period between nephrectomy and 18F-FDG PET/CT scans was 
9.5 (range: 0,5-180) months. 
The details of 18F-FDG PET/CT and ceCT results for all 
patients are shown in Table 1. The number of patients who 
had compatible results of 18F-FDG PET/CT and ceCT (overall 
concordance) was 7/22 (32%). The two imaging modalities 
showed concordant fi ndings in 19/22 patients (86%) 
(Kappa:0.67) for local recurrence (at the renal fossa, ipsilateral 
adrenal gland or ipsilateral regional lymph nodes) and in 
15/22 patients (68%) (Kappa:0.40) for distant metastases. 
The subgroup analysis of distant metastases was also done. 
The regions of distant metastases were distant lymph nodes 
(mediastinium/abdomen), lungs, liver, bone, and spleen. The 
number of patients who had concordant fi ndings for defi ning 
distant lymph nodes metastases was 19 (86%) (Kappa:0.70), 
lung metastases was 19 (86%) (Kappa:0.67), liver metastases 
was 20 (91%) (Kappa:0.64), bone metastases was 19 (86%) 
(Kappa:0.33), and spleen was 21 (95%). Kappa could not be 
calculated in one patient who had spleen metastases (Table 2).
Discussion 
Presence of metastatic disease is a strong predictor of poor 
survival in patients with RCC. About 20-30% of patients had 
metastatic disease at diagnosis and 20-40% of patients develop 
metastases during the course of disease. In the presence of 
metastases, the 5 year survival drops to below 10% [2-6]. 
Therefore, accurate staging is important to decide correct 
therapy management and to determine prognosis of disease. 
Nowadays, ceCT is one of the commonly used imaging methods 
to stage and restage RCC. However, ceCT has some limitations 
such as postoperative changes, make interpretation of ceCT of 
the renal bed diffi cult. ceCT is also risky for renal functional 
damage and allergy to contrast agent. 18F-FDG PET which is a 
functional imaging modality, also has limited sensitivity for 
evaluating metastatic RCC, especially for milimetric metastatic 
lesions [11,13,14]. Nowadays, 18F-FDG PET/CT that is a hybrid 
imaging modality, is a promising method for restaging of RCC 
[15-21]. In this study, we compared the results of 18F-FDG PET/
CT and ceCT in patients who had suspected lesions in ceCT for 
local recurrence and/or distant metastases.
 In our analysis, the overall concordance rate between 
the two imaging modalities was found as low as 32% (7/22 
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patients). There was concordance for local recurrence in 2/7 
patients, distant metastasis in 3/7 patients, for both local and 
distant metastasis in 2/7 patients. In the separate evaluation 
of local recurrence, the rates of concordance was 86% (19/22 
patients) (Kappa:0.67). In 5/19 patients, the results of both 
imaging methods were concordantly positive and in 14/19 
patients were concordantly negative. In one of the patients 
(patient 8) with concordantly positive ceCT and 18F-FDG PET/
CT results for local recurrence, one extra focus was shown 
by 18F-FDG PET/CT. In three patients (patients 10, 19 and 
22) there were foci reported on ceCT but not FDG avid on 
18F-FDG PET/CT. These foci were lymph nodes in 2 patients 
and suspected lesion in the renal fossa in 1 patient. Due to the 
limitations in resolution of PET systems, lesions <1cm may 
not be detectable by 18F-FDG PET/CT [19,21]. However, all of 
these 3 lesions were >1cm and none of them were FDG avid. 
Park, et al., compared FDG PET/CT to conventional imaging 
modalities for restaging of RCC because of high risk of local 
recurrence or distant metastasis [15]. FDG PET/CT had 92.6% 
negative predictive value in detecting recurrence or metastasis. 
In the same study, conventional methods had lower positive 
predictive value (75%) in detecting recurrence or metastasis. 
Heidenreich et al., reported that 3-43% false positive rate 
for CT in preoperative evaluation of lymph node in patients 
with RCC [22]. Türkvatan et al., published that the moderate 
agreement between pathology and CT for N staging of RCC 
(Kappa: 0.40) [23]. The limited role of CT in the differentiation 
of postoperative changes from residue or local recurrence is 
well known. In one of our patients, the differentiation between 
postoperative changes and recurrence was not possible for 
the lesion detected by ceCT in the renal fossa. No FDG uptake 
was seen in this focus and the other two lymph nodes in the 
follow up no recurrence were detected in the suspected areas. 
Although our results show relatively high concordance between 
CT and 18F-FDG PET/CT in 19/22 patients for local recurrence, 
it is still likely that 18F-FDG PET/CT is useful to exclusion of 
recurrence in suspected cases. 
The two imaging modalities showed concordant fi ndings in 
15/22 patients (68%) (Kappa:0.40) for distant metastases. When 
compared with local recurrence (Kappa:0.67), the concordance 
between the two methods was relatively low in detection of 
distant metastasis. This was probably because the whole body 
Table 1: The details of 18F-FDG PET/CT and CT results for all patients.
Local recurrence Distant metastases
CT PET CT PET
1 71 male - - Lung -
2 42 male - - lung, mediastinum lung,mediastinum
3 57 male - - mediastinum mediastinum
4 55 male - - lung, lymph nodes lung, lymph nodes, bone
5 61 male renal fossa renal fossa mediastinum mediastinum
6 69 male - - lung, mediastinum, bone lung, mediastinum, bone
7 74 female ipsilateral adrenal ipsilateral adrenal - -
8 53 female renal fossa renal fossa + ipsilateral surrenal - -
9 73 female - - Lung, mediastinum lung
10 43 man Ipsilateral lymph node - lung -
11 61 man - - liver -
12 73 female - - lung lung, mediastinum, bone
13 64 man ipsilateral lymph nvode ipsilateral lymph node - -
14 66 man - - liver -
15 68 female - - liver liver, spleen,lymph nodes 
16 34 female - - contralateal adrenal -
17 40 female ipsilateral adrenal ipsilateral adrenal liver, lymph nodes liver, lymph nodes
18 70 female - - thyroid -
19 48 man ipsilateral lymph node - - -
20 55 man - - Pleural effusion -
21 61 man - - Lung, bone, lymph nodes Lymph nodes
22 62 man renal fossa - - -
Table 2: The rates of concordance and discordance and calculated Kappa values 
for 18F-FDG PET/CT and CT.
Concordance Discordance Kappa
Local recurrence 19 (86%) 3 (14%) 0.67
Distant metastases 15 (68%) 7 (32%) 0.40
Lung 19 (86%) 3 (14%) 0.67
Liver 20 (91%) 2 (9%) 0.64
Bone 19 (86%) 3 (14%) 0.33
Lymph node 19 (86%) 3 (14%) 0.70
Spleen 21 (95%) 1 (5%)
Overall 7 (32%) 15 (68%)
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imaging tool 18F-FDG PET/CT has an additive value in the 
detection of distant metastasis, especially skeletal metastasis. 
The data reported by Aide et al., revealed that 18F-FDG PET/
CT is an effective method for evaluation of distant metastasis 
in the early postoperative staging of RCC [10]. The accuracy 
of 18F-FDG PET/CT in detecting distant metastasis was 94%, 
while the accuracy of ceCT was 89%. They emphasized that 
18F-FDG PET is especially needed for metabolic characterization 
if there is a solitary suspected lesion in a local advanced case 
[10]. In our study, although a detailed analysis of disease 
stage was not possible in all patients, 3 patients with distant 
metastasis had extensive lymphovascular invasion reported 
in the nephrectomy material. This reminds us the fact that 
18F-FDG PET/CT is more important in the follow up of patients 
with high risk for distant metastasis. When the subgroup 
analysis of the patients with distant metastasis was made, the 
highest compatibility ratios between ceCT and 18F-FDG PET/
CT was detected in distant lymph nodes (Kappa:0.70), lung 
(Kappa:0.67) and liver (Kappa:0.64). The correspondence for 
skeletal metastasis was quite low (Kappa:0.33). 
In our study, mediastinum is the most common localization 
of distant lymph node metastasis. The two imaging modalities 
showed concordant fi ndings in 20/22 patients (Kappa:0.75) for 
distant lymph node metastasis. In a patient with incompatible 
result, paratracheal-bronchopulmoner two lymph nodes and 
lung nodules with pathologic appearance were defi ned on ceCT. 
While multiple pathologic FDG uptake (SUVmax:12.4) were 
seen on lung nodules, there was no uptake of FDG in defi ned 
lymph nodes on ceCT. This situation can be explained with the 
limitation of 18F-FDG PET/CT in evaluation of lymph nodes 
adjacent to lesions with high FDG uptake. In another case, 
there was a lymph node that was not considered pathologic on 
ceCT, however it was FDG avid on 18F-FDG PET/CT. Although 
histopathological evaluation of lymph node is not possible, 
ceCT found inadequate for the evaluation of lymph node in this 
patient because of lung metastases as shown in both modalities 
and additional bone metastases detected by 18F-FDG PET/CT. 
Lung metastasis of RCC is frequently present in 0.5 to 2 
cm diameter, well-defi ned, solitary or multiple asymptomatic 
nodules [21]. Nodule size is an important in evaluation of lung 
metastasis. Kang, et al., have reported that the sensitivity 
of 18F-FDG PET and ceCT was 75% and 91% respectively for 
the detection of metastasis in RCC [11]. Although calculating 
sensitivity and specifi city in our study, the concordance for lung 
metastasis was positive in 19/22 patients (kappa:0.67). In the 
two patients with discordant results, while nodules <1cm were 
seen on ceCT, there was no FDG uptake in the nodules. There 
was no change in the size and SUVmax of the nodule on the 
18F-FDG PET/CT performed 6 months later for restaging. The 
follow up results of the other patient was uncertain but because 
the patient had pathological uptake in the mediastinal and 
abdominal lymph nodes shown by 18F-FDG PET/CT, assuming 
the disease is extensive, lung nodules could much probably be 
metastatic but 18F-FDG PET was not able detect them. On the 
ceCT scan of the last patient with discordant fi ndings, there 
was a focal ground-glass appearance. The 18F-FDG PET/CT 
of the same patient performed 3 months later was negative. 
As a result, 18F-FDG PET/CT truely ruled out metastasis in 
2/3 suspected patients. However it missed one patient with 
probably metastatic millimetric nodules. This reveals the 
complementary role of conventional ceCT and 18F-FDG PET/CT. 
The results were concordant in the 20/22 patients for liver 
lesions (2 positive and 18 negative), and were discordant in 
2/22 patients (Kappa:0.64). Both two patients with discordant 
results had hypodense lesions on ceCT (15mm and 20mm) 
but they were not FDG avid. Majhail et al have reported the 
sensitivity of 18F-FDG PET/CT in detecting lesions 1.5cm and 
2cm size as 83.3% and 92.9% respectively. They also revealed 
that 18F-FDG PET/CT can be a helpful complementary tool, 
especially if there are suspected lesions over 1.5cm to evaluate 
[13]. In the same study, it is also proposed that if a suspected 
lesion >1.5 cm is FDG avid, then biopsy should be performed. 
Conversely, if the lesion >1.5 cm does not show any FDG 
uptake, malignity cannot be ruled out and histopathological 
examination decision should be made by clinical correlation. 
In this study, in addition to the non-FDG avid two liver 
lesions, 1 adrenal lesion, 1 thyroid nodule (20mm ecopenic 
solid, aspiration biopsy: hypocellular) and pleural effusion 
was also detected in three patients respectively. These lesions 
were all FDG negative and no metastasis was detected at these 
sites in any of the patients in the follow up. Our data suggest 
that an FDG negative study helps in ruling out metastasis in 
suspected cases except for millimetric lesions. In one of the 
cases, abdominal lymph node and spleen involvement could 
be demonstrated by 18F-FDG PET/CT but not ceCT alone. 
Because the patient had liver metastasis, clinical approach did 
not change but the extension of the disease could be perfectly 
shown. 
Bone metastasis in RCC is often characterized by large, 
lytic, expansile lesions. Bone scintigraphy has modarete 
sensitivity as 10-60% for detection of these lesions [24]. 
However, it has been reported that sensitivity and accuracy of 
18F-FDG PET for detection of bone metastases may be as high 
as 100% [25]. In our study, the rate of discordance was 14% 
(3/22 patients) although ceCT showed no bone lesions in 2/24 
patients, 18F-FDG PET/CT showed widespread bone metastases. 
However, in 1/22 patient, 18F-FDG PET/CT failed to show the 
sclerotic-lytic mixed lesions on reported ceCT. 
There were some limitations of the study. The number 
of patients was small and histopathologic confi rmation of 
metastases could not be possible for every patient. In most 
patients, histopathologic details of the primary tumor could 
not be obtained because patients were referred from different 
centers. For this reason, 18F-FDG PET/CT results and histologic 
subtype/nuclear grade could not be compared. 
As a conclusion; 18F-FDG PET/CT is not enough alone in the 
detection of local recurrence and distant metastases of RCC. 
On the other hand, evaluation of 18F-FDG PET/CT and ceCT 
together signifi cantly improves the detection of RCC recurrence. 
A negative 18F-FDG PET/CT may contribute to exclusion of 
suspected metastatic lesions, unless they are milimetric. 
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